1. Singapore Stocks

  2. •

    Health technology

  3. •

    Medical specialties
VicPlas International Ltd.

VicPlas International Ltd.

SSGX:569
0.07
SGD
+0.00
(-1.52%)
47.02MMarket Cap
Mar 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.19
0.14
0.16
0.16
0.13
0.14
0.16
0.18
0.22
0.26
0.25
0.2
- -
- -
Basic EPS, GAAP
0.01
-0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.02
0.02
0.01
- -
- -
- -
Free Cash Flow per Basic Share
- -
-0.02
0.01
0.02
- -
-0.01
-0.01
0.01
0.01
-0.01
0.02
-0.02
- -
- -
Dividend per Share
- -
- -
- -
0.01
0.01
0.01
- -
0.01
- -
- -
- -
- -
- -
- -
Book Value per Share
0.11
0.11
0.12
0.12
0.12
0.12
0.12
0.12
0.14
0.15
0.15
0.15
- -
0.13
Tangible Book Value per Share
0.11
0.11
0.12
0.11
0.11
0.11
0.12
0.12
0.14
0.15
0.15
0.14
- -
0.13
Basic Weighted Avg Shares
458
464
466
488
500
503
505
507
509
511
511
511
511
511
Sales/Revenue/Turnover
86
63
74
76
64
70
80
89
114
131
129
102
- -
- -
Operating Margin (%)
12.13
-4.05
8.34
10.21
0.11
-0.28
1.91
3.95
5.4
4.6
3.07
-4.78
- -
- -
Depreciation Expense
4
4
4
4
3
4
4
6
6
6
6
7
- -
- -
Net Income, GAAP
6
-4
6
5
3
4
4
5
10
9
4
-1
- -
- -
Effective Tax Rate (%)
29.48
- -
19.13
19.96
15.73
- -
- -
31.72
15.45
19.69
24.44
- -
- -
- -
Profit Margin (%)
6.44
-6.43
7.79
7.07
5.03
5.15
5.28
5.61
9.13
6.76
3.28
-1.33
- -
- -
Working Capital
31
27
31
33
34
29
26
26
44
42
42
26
- -
19
LT Debt
- -
- -
1
1
- -
- -
- -
4
14
14
10
13
- -
12
Total Equity
51
50
56
58
58
59
61
62
72
78
79
75
- -
69
Return on Invested Capital (%)
11.31
- -
10.43
8.87
5.32
- -
- -
5.15
6.8
5.02
3.07
- -
- -
- -
Return on Capital (%)
11.4
- -
10.63
9.24
5.52
- -
- -
7.57
13.01
9.65
5.05
- -
- -
- -
Return on Common Equity (%)
11.52
-8.13
10.95
9.42
5.49
6.17
7.09
8.15
15.6
11.79
5.4
-1.78
- -
- -

Capital Structure

SGD

•

in mil. unless spec.
Jan'25
Jul'25
Jan'26
ST Debt
27
- -
32
LT Borrowings
- -
- -
1
LT Finance Leases
11
- -
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
511
511
511
Market Capitalization
47
47
47

Working Capital

SGD

•

in mil. unless spec.
Jan'25
Jul'25
Jan'26
Total Current Assets
69
- -
72
Cash, Cash Equivalents & STI
7
- -
7
Accounts Receivable, Net
27
- -
28
Inventories
18
- -
17
Total Current Liabilities
46
- -
52
Payables & Accruals
- -
- -
- -
ST Debt
27
- -
32
Deferred Revenue
- -
- -
- -

Growth Rates

SGD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

SGD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
102
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

SGD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Dividends Per Share

SGD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Walter Tarca
Full Time Employees
1,111
Sector
Health technology
Industry
Medical specialties
Address
35 Joo Koon Circle Singapore CE Singapore 629110
IPO Date
Apr 22, 1999
Website
vicplas.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Vicplas International Ltd functions as an investment holding entity based in Singapore, operating through two primary business divisions: medical devices and piping systems. The company, established in 1993, engages in the research, design, development, and manufacturing of both sterile and non-sterile medical devices through its Forefront Medical subsidiary. Its global manufacturing footprint for medical devices includes facilities in Singapore, China (Xiamen and Changzhou), the United Kingdom (Arrow Medical), and a recently expanded plant in Juarez, Mexico, which is expected to bolster its capabilities for key markets like the USA, Europe, and Japan. Furthermore, Vicplas, through its Vicplas Pipes segment, manufactures and distributes a comprehensive range of heavy-metal-free plastic piping systems and fittings. These products serve diverse applications such as waste and potable water management for residential, commercial, and industrial structures, as well as underground conduits for electrical and telecommunications cabling. The company's piping solutions are widely utilized in Singapore and Malaysia, with certifications from the Singapore Green Building Council highlighting its commitment to sustainability. Vicplas International reported a revenue increase of 13.1% to S$115.8 million in FY2025, primarily driven by growth in its medical devices segment, although it recorded a net loss. The company's medical device revenue saw a 22.3% increase in FY2025 due to a rise in customer orders as post-pandemic inventory levels adjusted. Vicplas International Ltd is a subsidiary of Venner Capital S.A.